These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26999703)

  • 1. Zoledronic acid increases the circulating soluble RANKL level in mice, with a further increase in lymphocyte-derived soluble RANKL in zoledronic acid- and glucocorticoid-treated mice stimulated with bacterial lipopolysaccharide.
    Abe T; Sato T; Kokabu S; Hori N; Shimamura Y; Sato T; Yoda T
    Cytokine; 2016 Jul; 83():1-7. PubMed ID: 26999703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data in support of the bone analysis of NOD-SCID mice treated with zoledronic acid and prednisolone.
    Hori N; Abe T; Sato T; Kokabu S; Shimamura Y; Sato T; Yoda T
    Data Brief; 2016 Jun; 7():1486-90. PubMed ID: 27182545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
    Liu J; Xu K; Wen G; Guo H; Li S; Wu X; Dai R; Sheng Z; Liao E
    Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
    de Molon RS; Shimamoto H; Bezouglaia O; Pirih FQ; Dry SM; Kostenuik P; Boyce RW; Dwyer D; Aghaloo TL; Tetradis S
    J Bone Miner Res; 2015 Sep; 30(9):1627-40. PubMed ID: 25727550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis.
    Dovio A; Generali D; Tampellini M; Berruti A; Tedoldi S; Torta M; Bonardi S; Tucci M; Allevi G; Aguggini S; Bottini A; Dogliotti L; Angeli A
    Osteoporos Int; 2008 Jan; 19(1):113-7. PubMed ID: 17703272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Glucocorticoid and Bone. Significance of serum soluble RANKL measurement in patients under glucocorticoid therapy].
    Kaneko K; Kawai S
    Clin Calcium; 2014 Sep; 24(9):1361-70. PubMed ID: 25177009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
    Kananen K; Volin L; Laitinen K; Ruutu T; Välimäki MJ
    Osteoporos Int; 2006; 17(5):724-30. PubMed ID: 16437190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
    Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune modulation of CD4
    Liu H; Wang SH; Chen SC; Chen CY; Lo JL; Lin TM
    BMC Immunol; 2016 Nov; 17(1):45. PubMed ID: 27887569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma.
    Martini G; Gozzetti A; Gennari L; Avanzati A; Nuti R; Lauria F
    Haematologica; 2006 Dec; 91(12):1720-1. PubMed ID: 17145616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
    Hamed EA; Mohamed NA; El-Metwally TH; Kamal MM
    J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble RANKL Cleaved from Activated Lymphocytes by TNF-α-Converting Enzyme Contributes to Osteoclastogenesis in Periodontitis.
    Kanzaki H; Makihira S; Suzuki M; Ishii T; Movila A; Hirschfeld J; Mawardi H; Lin X; Han X; Taubman MA; Kawai T
    J Immunol; 2016 Nov; 197(10):3871-3883. PubMed ID: 27815441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
    Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
    BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.
    McDonald MM; Dulai S; Godfrey C; Amanat N; Sztynda T; Little DG
    Bone; 2008 Oct; 43(4):653-62. PubMed ID: 18582604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
    Quinn JE; Brown LG; Zhang J; Keller ET; Vessella RL; Corey E
    Prostate Cancer Prostatic Dis; 2005; 8(3):253-9. PubMed ID: 15999121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells.
    Bringmann A; Schmidt SM; Weck MM; Brauer KM; von Schwarzenberg K; Werth D; Grünebach F; Brossart P
    Leukemia; 2007 Apr; 21(4):732-8. PubMed ID: 17301819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of zinc supplementation against cadmium-induced oxidative stress and the RANK/RANKL/OPG system imbalance in the bone tissue of rats.
    Brzóska MM; Rogalska J
    Toxicol Appl Pharmacol; 2013 Oct; 272(1):208-20. PubMed ID: 23726800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.